Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1

Bharat Biotech's Covaxin found to be safe, induced immune response in Phase-1

Money Control

Bharat Biotech's Covaxin was granted restricted emegency use approval in 'clinical trial mode' on January 2.

Bharat Biotech's coronavirus vaccine Covaxin has been found to be well-tolerated and produced an immune response, says the Phase-1 interim data published by the company in the peer-reviewed British medical journal Lancet.

The findings come at a time amid reports that some healthcare workers, including doctors, were not turning up to take the indigenously developed jab, which was given the emergency approval under the "trial mode", over safety concerns.

Disclaimer: This is an automatically aggregated article/story by a computer program and has not been created or edited by Newsdig.in.

World COVID19 Meter

113834374

Cases

89401906

Recovered

2525295

Deaths
Last updated: GMT
Advt
Advt
Advt
sitemap Disclaimer
Newsdig.in 2019